CAP

AIIB Launches Report on Transformative Concept of Defining Nature as Infrastructure

Retrieved on: 
Saturday, December 2, 2023

DUBAI, UAE, Dec. 2, 2023 /PRNewswire/ -- The Asian Infrastructure Investment Bank (AIIB) today launched its 2023 Asian Infrastructure Finance report , titled Nature as Infrastructure, with a panel discussion at its COP28 pavilion.

Key Points: 
  • DUBAI, UAE, Dec. 2, 2023 /PRNewswire/ -- The Asian Infrastructure Investment Bank (AIIB) today launched its 2023 Asian Infrastructure Finance report , titled Nature as Infrastructure, with a panel discussion at its COP28 pavilion.
  • Viewing Nature as Infrastructure offers a transformative approach for recognizing the value of nature and enhancing investment in the protection of nature and biodiversity.
  • It includes nature-based solutions, direct investments into nature assets to sustain critical infrastructure-like services and directing more finance toward nature.
  • Potential solutions toward a nature-positive future were discussed during the panel and is explored further in AIIB's 2023 Asian Infrastructure Finance Report: "Nature as Infrastructure."

ATALAN ADDS TRICORE TO ITS TECHNOLOGY-ENABLED CLINICAL PARTNERSHIP, PROVIDING GREATER ACCESS TO THE BEST IN LABORATORY MEDICINE

Retrieved on: 
Wednesday, November 29, 2023

MILWAUKEE, Nov. 29, 2023 /PRNewswire/ -- Atalan, the technology-enabled clinical partnership providing doctors and medical centers unprecedented access to a vetted network of the nation's foremost clinical laboratories, announced today the addition of TriCore to its network. TriCore is an independent, not-for-profit, clinical laboratory headquartered in Albuquerque, N.M. providing more than 2,900 full-service, state-of-the-art laboratory tests to healthcare professionals and their patients, as well as analytics and research services supporting healthcare and scientific organizations worldwide.

Key Points: 
  • Atalan's growing list of laboratory partners are strategically vetted and selected to add to the cumulative strength of the network.
  • By recruiting and partnering with best-in-class health system laboratories like TriCore, the company aims to be a catalyst for growth and sustainability.
  • "We are very pleased to announce the addition of TriCore to our growing team of exceptional clinical laboratory partners," said Steve Serota, Chief Executive Officer of Atalan.
  • "TriCore has a relentless drive to improve processes, eliminate errors and empower partners to improve healthcare through accurate diagnoses.

Senhwa Biosciences Received US FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection

Retrieved on: 
Tuesday, November 21, 2023

The trial is a phase II multi-center, randomized-controlled interventional prospective study, and the purpose of this trial is to investigate whether early intervention of Silmitasertib restrains the progression of CAP by inhibiting the elevated cytokine release associated with SARS-CoV-2 and Influenza viruses.

Key Points: 
  • The trial is a phase II multi-center, randomized-controlled interventional prospective study, and the purpose of this trial is to investigate whether early intervention of Silmitasertib restrains the progression of CAP by inhibiting the elevated cytokine release associated with SARS-CoV-2 and Influenza viruses.
  • Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses.
  • "Senhwa regards this phase II as the proof-of-concept study to demonstrate Silmitasertib can be a therapeutic strategy that are not restricted to only a specific viral infection, but applicable to various viruses," said Jin-Ding Huang, CEO of Senhwa Biosciences, Inc.
  • Prior to this phase II study, Silmitasertib was investigated in two investigator-initiated trials (IIT) in the United States and has showed clinical benefits by accelerating the recovery speed in patients with moderate symptoms of COVID-19.

Wealth Solutions Report Announces 2024 Awards And Recognition Calendar

Retrieved on: 
Tuesday, November 21, 2023

NEW YORK, Nov. 21, 2023 /PRNewswire/ -- Wealth Solutions Report (WSR) – the fast-growing B2B digital media platform featuring wealth management-focused commentary, insights and analysis – today announced its awards and recognition schedule for 2024, encompassing the WSR Wealth Exemplar Awards, the WSR Pathfinder Awards and multiple recognition lists for top individual and firm leaders in the wealth management industry.

Key Points: 
  • NEW YORK, Nov. 21, 2023 /PRNewswire/ -- Wealth Solutions Report (WSR) – the fast-growing B2B digital media platform featuring wealth management-focused commentary, insights and analysis – today announced its awards and recognition schedule for 2024, encompassing the WSR Wealth Exemplar Awards, the WSR Pathfinder Awards and multiple recognition lists for top individual and firm leaders in the wealth management industry.
  • Larry Roth, Founder and CEO of Wealth Solutions Report, said, "Our awards and recognition lists have encouraged the wealth management industry, spotlighted excellence and, in the case of the Pathfinder Awards, provided a voice for professionals of underrepresented backgrounds.
  • The invitation-only Wealth Exemplar Awards celebrate excellence in the wealth management industry, honoring outstanding firms across multiple categories, trendsetting and industry-shaping M&A transactions, and a bold, visionary Person of the Year who has implemented change in the wealth management industry.
  • Through these awards and recognition lists, we established industry traditions that we will bring to a new level in 2024."

Colombia Set to Cull Wild Hippo Herd, Sparks Eco-Revolution: BloodSweaT™ Seeks to Save Hippos with Humane Relocation and Inaugural Products

Retrieved on: 
Monday, November 20, 2023

MIAMI, Nov. 20, 2023 /PRNewswire/ -- Humanitarian organization, BloodSweaT officially announced its launch to address the ongoing Colombian hippo crisis and imminent herd culling*, tackling the eco-challenge with relocation efforts while exploring the unique properties of naturally made hippo "blood sweat" in innovative new products.

Key Points: 
  • "I toured the most diverse ecosystem on our planet and we talked to the folks who live around the waterways and towns where the hippos roam," explained Dziadik.
  • "I entered the Magdalena River and encountered a large wild male hippo – I named him Hugo.
  • But when this happens in a river, they occasionally float off while they sleep, widening their range to unknown locations downstream."
  • The rapidly breeding populations of hippos in the area have risen to unknown numbers and locations.

EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

Retrieved on: 
Thursday, December 14, 2023

The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).

Key Points: 
  • The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).
  • One major characteristic of sCAP patients is that their immune system becomes dysregulated, which results in inflammation.
  • The results reported, support the currently ongoing investigation of trimodulin in artificial ventilated patients with sCAP with evidence of significant inflammation (ESsCAPE trial).
  • In addition, trimodulin is currently also in development for the treatment of hospitalized, oxygen-supported patients with non-severe CAP, including COVID-19 (TRICOVID trial).

Study demonstrates clinical utility of polygenic risk scores for cardiovascular disease in multiple ancestries

Retrieved on: 
Thursday, November 9, 2023

NEW YORK, Nov. 9, 2023 /PRNewswire/ --Allelica, a leading provider of clinical bioinformatics technology, has announced its scientific team's publication of their latest research in Nature Communications. The publication, "Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments", builds on the company's ongoing efforts to make polygenic risk scores (PRSs) for coronary artery disease (CAD) accessible in healthcare settings for individuals of all ancestries. This research marks a significant milestone in Allelica's mission to revolutionize healthcare by harnessing the power of PRS. 

Key Points: 
  • The publication, "Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments", builds on the company's ongoing efforts to make polygenic risk scores (PRSs) for coronary artery disease (CAD) accessible in healthcare settings for individuals of all ancestries.
  • Key findings of the publication include:
    Allelica's CAD PRSs identify individuals at high genetic risk of disease across all major genetic ancestry groups.
  • Using high CAD PRS as a risk factor leads to more accurate clinical risk assessments compared to models that don't use genetic information.
  • Our results highlight the transformative potential of polygenic risk scores to identify this risk and use it in clinical risk assessments for one of the most common, and preventable diseases - coronary artery disease.

Breaking Forecast Boundaries: The California Annual Precipitation Report Delivers Water Year Clarity Beyond El Niño's Reach

Retrieved on: 
Tuesday, November 7, 2023

Weather Tools, Inc. unveils the 2023-24 California Annual Precipitation (CAP) report today, emphasizing that water year precipitation is influenced by factors beyond El Niño alone.

Key Points: 
  • Weather Tools, Inc. unveils the 2023-24 California Annual Precipitation (CAP) report today, emphasizing that water year precipitation is influenced by factors beyond El Niño alone.
  • No other California water year precipitation forecast has come close to doing the same, making it the most accurate and reliable water year precipitation forecast in California.
  • While strong El Niño conditions are expected to persist into the spring of 2024, past El Niño events have shown significant variation in their impact on California precipitation.
  • In addition to the water year precipitation forecast, customers receive monthly progress reports with information on how the water year is unfolding.

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

Retrieved on: 
Monday, November 6, 2023

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.

Key Points: 
  • The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
  • Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  for presentation.
  • The two abstracts show:
    the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
  • the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.

Granite Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, October 31, 2023

Granite Construction Incorporated (NYSE: GVA) today announced results for the quarter ended September 30, 2023.

Key Points: 
  • Granite Construction Incorporated (NYSE: GVA) today announced results for the quarter ended September 30, 2023.
  • Gross profit increased $52 million to $167 million compared to $115 million for the same period in the prior year.
  • "I am pleased with our third quarter performance,” said Kyle Larkin, Granite President and Chief Executive Officer.
  • Three and Nine Months ended September 30, 2023 (Unaudited - dollars in thousands)
    Three Months Ended September 30,
    Nine Months Ended September 30,